CAS NO: | 50-32-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Benzo[a]pyrene showslung carcinogenicityin animal models, and it is frequently used in chemoprevention studies. | ||||||||||||||||
体内研究 (In Vivo) | Statistically significant decrease is observed at 7 weeks in females receiving 1.0 mg Benzo[a]pyrene (B[a]P) compare with the vehicle group. As lung tumorigenesis induced by Benzo[a]pyrene is dose dependent in female A/J mice. The incidence of hyperplasia values in females treating with 0.25, 0.50, and 1.0 mg Benzo[a]pyrene are significantly higher than in the vehicle-treated group. The incidence of adenoma in females receiving 1.0 mg Benzo[a]pyrene is significantly higher than in the vehicle group. The multiplicity of hyperplasia in females receiving 0.50 or 1.0 mg Benzo[a]pyrene is significantly higher than in the vehicle group. The multiplicity of adenoma in the group treated with 1.0 mg is also significantly higher than in the vehicle group. The incidences of hyperplasia and adenoma in female A/J mice are significantly increased by Benzo[a]pyrene in a dose-dependent manner[1]. Benzo[a]pyrene induces an average of 9.38±1.75 tumors with an average tumor load of 19.53±3.81 mm3(P<0.05 compare to control). Benzo[a]pyrene administration significantly (P<0.05) decreases cAMP levels in tumors with adjacent lung tissues. The expression level of PDE4D gene is also increased by Benzo[a]pyrene administration[2]. | ||||||||||||||||
分子量 | 252.31 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C20H12 | ||||||||||||||||
CAS 号 | 50-32-8 | ||||||||||||||||
中文名称 | 苯并[a]芘 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 25 mg/mL(99.08 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|